BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 19089463)

  • 1. Prospective assessment of chemotherapy-induced peripheral neuropathy due to weekly paclitaxel in patients with advanced or metastatic breast cancer (CSP-HOR 02 study).
    Kuroi K; Shimozuma K; Ohashi Y; Hisamatsu K; Masuda N; Takeuchi A; Aranishi T; Morita S; Ohsumi S; Hausheer FH
    Support Care Cancer; 2009 Aug; 17(8):1071-80. PubMed ID: 19089463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Feasibility and validity of the Patient Neurotoxicity Questionnaire during taxane chemotherapy in a phase III randomized trial in patients with breast cancer: N-SAS BC 02.
    Shimozuma K; Ohashi Y; Takeuchi A; Aranishi T; Morita S; Kuroi K; Ohsumi S; Makino H; Mukai H; Katsumata N; Sunada Y; Watanabe T; Hausheer FH
    Support Care Cancer; 2009 Dec; 17(12):1483-91. PubMed ID: 19330359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemotherapy-induced peripheral neuropathy-patient-reported outcomes compared with NCI-CTCAE grade.
    Tan AC; McCrary JM; Park SB; Trinh T; Goldstein D
    Support Care Cancer; 2019 Dec; 27(12):4771-4777. PubMed ID: 30972648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Taxane-induced peripheral neuropathy and health-related quality of life in postoperative breast cancer patients undergoing adjuvant chemotherapy: N-SAS BC 02, a randomized clinical trial.
    Shimozuma K; Ohashi Y; Takeuchi A; Aranishi T; Morita S; Kuroi K; Ohsumi S; Makino H; Katsumata N; Kuranami M; Suemasu K; Watanabe T; Hausheer FH
    Support Care Cancer; 2012 Dec; 20(12):3355-64. PubMed ID: 22584733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The relationship between peripheral neuropathy and efficacy in second-line chemotherapy for unresectable advanced gastric cancer: a prospective observational multicenter study protocol (IVY).
    Tanioka H; Nagasaka T; Uno F; Inoue M; Okita H; Katata Y; Kanzaki H; Kuramochi H; Satake H; Shindo Y; Doi A; Nasu J; Yamashita H; Yamaguchi Y
    BMC Cancer; 2019 Oct; 19(1):941. PubMed ID: 31604467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cryotherapy for the prevention of weekly paclitaxel-induced peripheral adverse events in breast cancer patients.
    Shigematsu H; Hirata T; Nishina M; Yasui D; Ozaki S
    Support Care Cancer; 2020 Oct; 28(10):5005-5011. PubMed ID: 32036471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase IIA trial of acupuncture to reduce chemotherapy-induced peripheral neuropathy severity during neoadjuvant or adjuvant weekly paclitaxel chemotherapy in breast cancer patients.
    Bao T; Seidman AD; Piulson L; Vertosick E; Chen X; Vickers AJ; Blinder VS; Zhi WI; Li Q; Vahdat LT; Dickler MN; Robson ME; Mao JJ
    Eur J Cancer; 2018 Sep; 101():12-19. PubMed ID: 30007894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of Cryotherapy on Objective and Subjective Symptoms of Paclitaxel-Induced Neuropathy: Prospective Self-Controlled Trial.
    Hanai A; Ishiguro H; Sozu T; Tsuda M; Yano I; Nakagawa T; Imai S; Hamabe Y; Toi M; Arai H; Tsuboyama T
    J Natl Cancer Inst; 2018 Feb; 110(2):141-148. PubMed ID: 29924336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and genetic predictors of paclitaxel neurotoxicity based on patient- versus clinician-reported incidence and severity of neurotoxicity in the ICON7 trial.
    Park SB; Kwok JB; Asher R; Lee CK; Beale P; Selle F; Friedlander M
    Ann Oncol; 2017 Nov; 28(11):2733-2740. PubMed ID: 29117336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A questionnaire survey of physicians' perspectives regarding the assessment of chemotherapy-induced peripheral neuropathy in patients with breast cancer.
    Kuroi K; Shimozuma K; Ohashi Y; Takeuchi A; Aranishi T; Morita S; Ohsumi S; Watanabe T; Bain S; Hausheer FH
    Jpn J Clin Oncol; 2008 Nov; 38(11):748-54. PubMed ID: 18845520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the efficacy of cryotherapy and compression therapy for preventing nanoparticle albumin-bound paclitaxel-induced peripheral neuropathy: A prospective self-controlled trial.
    Kanbayashi Y; Sakaguchi K; Ishikawa T; Ouchi Y; Nakatsukasa K; Tabuchi Y; Kanehisa F; Hiramatsu M; Takagi R; Yokota I; Katoh N; Taguchi T
    Breast; 2020 Feb; 49():219-224. PubMed ID: 31901783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cryocompression to Reduce Peripheral Neuropathy in Gynecologic Cancer: A Randomized Controlled Trial.
    Anastasio MK; Unnithan S; Scott A; Hayes T; Shah S; Moss HA; Erkanli A; Havrilesky LJ
    Obstet Gynecol; 2023 Dec; 142(6):1459-1467. PubMed ID: 37883997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized trial to evaluate the preventive effect of lafutidine on chemotherapy-induced peripheral neuropathy in patients treated with carboplatin and paclitaxel for lung cancer.
    Cho K; Saikawa H; Hashimoto T; Katagiri H; Owada Y; Yakuwa K; Fujimura I; Utsumi Y; Akiyama M; Nagashima H; Takahashi F; Maemondo M
    Ann Palliat Med; 2023 Nov; 12(6):1136-1145. PubMed ID: 37731302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Are we mis-estimating chemotherapy-induced peripheral neuropathy? Analysis of assessment methodologies from a prospective, multinational, longitudinal cohort study of patients receiving neurotoxic chemotherapy.
    Molassiotis A; Cheng HL; Lopez V; Au JSK; Chan A; Bandla A; Leung KT; Li YC; Wong KH; Suen LKP; Chan CW; Yorke J; Farrell C; Sundar R
    BMC Cancer; 2019 Feb; 19(1):132. PubMed ID: 30736741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hemoglobin, Body Mass Index, and Age as Risk Factors for Paclitaxel- and Oxaliplatin-Induced Peripheral Neuropathy.
    Mizrahi D; Park SB; Li T; Timmins HC; Trinh T; Au K; Battaglini E; Wyld D; Henderson RD; Grimison P; Ke H; Geelan-Small P; Marker J; Wall B; Goldstein D
    JAMA Netw Open; 2021 Feb; 4(2):e2036695. PubMed ID: 33587134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Longitudinal validation and comparison of the Chinese version of the European Organization for Research and Treatment of Cancer Quality of Life-Chemotherapy-Induced Peripheral Neuropathy Questionnaire (EORTC QLQ-CIPN20) and the Functional Assessment of Cancer-Gynecologic Oncology Group-Neurotoxicity subscale (FACT/GOG-Ntx).
    Cheng HL; Molassiotis A
    Asia Pac J Clin Oncol; 2019 Feb; 15(1):56-62. PubMed ID: 29873180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic tools should be used for the diagnosis of chemotherapy induced peripheral neuropathy in breast cancer patients receiving taxanes.
    van Haren F; van den Heuvel S; Ligtenberg M; Vissers K; Steegers M
    Cancer Rep (Hoboken); 2022 Oct; 5(10):e1577. PubMed ID: 34687287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the effect of N-acetylcysteine on the prevention and amelioration of paclitaxel-induced peripheral neuropathy in breast cancer patients: a randomized controlled study.
    Khalefa HG; Shawki MA; Aboelhassan R; El Wakeel LM
    Breast Cancer Res Treat; 2020 Aug; 183(1):117-125. PubMed ID: 32601973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acupuncture for Chemotherapy-Induced Peripheral Neuropathy in Breast Cancer Survivors: A Randomized Controlled Pilot Trial.
    Lu W; Giobbie-Hurder A; Freedman RA; Shin IH; Lin NU; Partridge AH; Rosenthal DS; Ligibel JA
    Oncologist; 2020 Apr; 25(4):310-318. PubMed ID: 32297442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemotherapy-induced peripheral neurotoxicity can be misdiagnosed by the National Cancer Institute Common Toxicity scale.
    Frigeni B; Piatti M; Lanzani F; Alberti P; Villa P; Zanna C; Ceracchi M; Ildebrando M; Cavaletti G
    J Peripher Nerv Syst; 2011 Sep; 16(3):228-36. PubMed ID: 22003937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.